Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
CNY 1.71
(-1.16%)
CNY 1.71
(-1.16%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.54 Billion CNY | -68.31% |
| 2022 | 4.48 Billion CNY | 24.62% |
| 2021 | 3.59 Billion CNY | 3808.31% |
| 2020 | 92 Million CNY | -84.21% |
| 2019 | 582.66 Million CNY | 40.75% |
| 2018 | 413.95 Million CNY | -30.52% |
| 2017 | 595.79 Million CNY | 75.75% |
| 2016 | 339 Million CNY | 54.98% |
| 2015 | 218.74 Million CNY | -67.77% |
| 2014 | 678.72 Million CNY | 864.99% |
| 2013 | 70.33 Million CNY | -81.69% |
| 2012 | 384.21 Million CNY | -20.77% |
| 2011 | 484.95 Million CNY | 151.41% |
| 2010 | 192.89 Million CNY | 314.49% |
| 2009 | 46.53 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 44.65 Million CNY | -83.52% |
| 2024 Q3 | 30.5 Million CNY | -85.1% |
| 2024 Q2 | 204.75 Million CNY | 358.47% |
| 2023 Q3 | 481.05 Million CNY | 90.63% |
| 2023 Q4 | 271.04 Million CNY | -43.66% |
| 2023 FY | 1.42 Billion CNY | -68.31% |
| 2023 Q1 | 477.2 Million CNY | 8.54% |
| 2023 Q2 | 252.34 Million CNY | -47.12% |
| 2022 Q2 | 1.87 Billion CNY | 52.51% |
| 2022 FY | 4.48 Billion CNY | 24.62% |
| 2022 Q4 | 439.66 Million CNY | -53.0% |
| 2022 Q1 | 1.23 Billion CNY | 2.4% |
| 2022 Q3 | 935.42 Million CNY | -50.14% |
| 2021 Q3 | 1.31 Billion CNY | 67.5% |
| 2021 Q4 | 1.2 Billion CNY | -8.73% |
| 2021 FY | 3.59 Billion CNY | 3808.31% |
| 2021 Q1 | 292.85 Million CNY | 39.35% |
| 2021 Q2 | 785.74 Million CNY | 168.3% |
| 2020 Q2 | 82.66 Million CNY | 262.09% |
| 2020 Q3 | 198.66 Million CNY | 140.31% |
| 2020 Q4 | 210.16 Million CNY | 5.79% |
| 2020 FY | 92 Million CNY | -84.21% |
| 2020 Q1 | -51 Million CNY | -212.4% |
| 2019 FY | 582.66 Million CNY | 40.75% |
| 2019 Q4 | 45.37 Million CNY | -76.24% |
| 2019 Q1 | 130.09 Million CNY | 245.77% |
| 2019 Q2 | 216.26 Million CNY | 66.23% |
| 2019 Q3 | 190.93 Million CNY | -11.71% |
| 2018 Q3 | 200.83 Million CNY | -18.44% |
| 2018 FY | 413.95 Million CNY | -30.52% |
| 2018 Q4 | -89.24 Million CNY | -144.44% |
| 2018 Q2 | 246.25 Million CNY | 338.88% |
| 2018 Q1 | 56.11 Million CNY | -73.89% |
| 2017 Q1 | 197.78 Million CNY | 36.8% |
| 2017 Q2 | 87.3 Million CNY | -55.86% |
| 2017 Q3 | 95.79 Million CNY | 9.73% |
| 2017 Q4 | 214.91 Million CNY | 124.35% |
| 2017 FY | 595.79 Million CNY | 75.75% |
| 2016 Q2 | 63.65 Million CNY | 16.38% |
| 2016 FY | 339 Million CNY | 54.98% |
| 2016 Q4 | 144.58 Million CNY | 90.07% |
| 2016 Q1 | 54.69 Million CNY | 112.3% |
| 2016 Q3 | 76.06 Million CNY | 19.5% |
| 2015 Q2 | 116.52 Million CNY | 166.17% |
| 2015 Q4 | 25.76 Million CNY | -21.15% |
| 2015 Q3 | 32.67 Million CNY | -71.96% |
| 2015 Q1 | 43.78 Million CNY | 331.65% |
| 2015 FY | 218.74 Million CNY | -67.77% |
| 2014 FY | 678.72 Million CNY | 864.99% |
| 2014 Q3 | 20.53 Million CNY | -96.81% |
| 2014 Q1 | 33.74 Million CNY | 41.92% |
| 2014 Q4 | -18.89 Million CNY | -192.03% |
| 2014 Q2 | 643.34 Million CNY | 1806.65% |
| 2013 FY | 70.33 Million CNY | -81.69% |
| 2013 Q2 | -967.87 Thousand CNY | -102.04% |
| 2013 Q3 | 42.92 Thousand CNY | 104.44% |
| 2013 Q1 | 47.48 Million CNY | 345.83% |
| 2013 Q4 | 23.77 Million CNY | 55287.92% |
| 2012 Q2 | 150.67 Million CNY | -7.42% |
| 2012 Q4 | 10.65 Million CNY | -82.29% |
| 2012 Q1 | 162.74 Million CNY | 5.22% |
| 2012 Q3 | 60.14 Million CNY | -60.09% |
| 2012 FY | 384.21 Million CNY | -20.77% |
| 2011 FY | 484.95 Million CNY | 151.41% |
| 2011 Q3 | 185.17 Million CNY | 0.0% |
| 2011 Q4 | 154.67 Million CNY | -16.47% |
| 2010 FY | 192.89 Million CNY | 314.49% |
| 2009 FY | 46.53 Million CNY | 0.0% |